

Fagron issues new shares to finance acquisition of AnazaoHealth

As announced on 11 May 2015, Fagron has signed an agreement to acquire AnazaoHealth, a leading sterile compounding pharmacy in the United States specialized in nuclear, pain and intrathecal compounding. The acquisition will be paid for 40% in Fagron shares and the remainder will be paid in cash.

Today Fagron announces it has increased the share capital by an amount corresponding to US\$ 10 million through the issue of 224,133 new shares within the authorized capital.

The number of Fagron shares with voting rights is 31,667,794. The total number of voting rights (denominator) is 31,667,794. The share capital is € 324,514,856.31.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

Fagron profile

Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimizing and innovating pharmaceutical compounding. Fagron offers Fagron Compounding Services, Fagron Trademarks and Fagron Compounding Essentials to pharmacies, hospitals and patients in 32 countries worldwide. Pharmaceutical compounding is an essential part of pharmaceutical care that enables prescribers and pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D department consists of 45 researchers and more than 300 pharmacists who are working continually on developing new concepts, vehicles and formulations to treat an increasing number of patients with tailor-made compounded medication. The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Marieke Palstra
Global Investor Relations Director
Tel. +31 88 33 11 213
marieke.palstra@fagron.com
investors.fagron.com

¹ This press release was sent out by Fagron NV and Fagron BV.

